Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.
The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers. In addition to ZN-c3, Zentalis’ pipeline includes programs targeting Polo-like kinase 1 (PLK1) and other novel oncogenic pathways. Preclinical studies conducted by the company have demonstrated promising activity across multiple tumor models, supporting further advancement of these candidates into human trials.
Zentalis applies an integrated discovery and development model, combining computational chemistry, structural biology and in-house medicinal chemistry to accelerate the identification of potent and selective drug candidates. The company collaborates with leading contract research organizations and academic institutions to support its preclinical and clinical research programs, with the goal of streamlining the path from discovery through clinical proof-of-concept.
Founded in 2017 and headquartered in New Haven, Connecticut, Zentalis Pharmaceuticals completed its initial public offering in 2020. The company is led by President and Chief Executive Officer Robert Farrell, Ph.D., whose experience in oncology drug discovery guides the organization’s strategic direction. Zentalis continues to advance its oncology pipeline with the aim of bringing novel treatment options to patients worldwide.
AI Generated. May Contain Errors.
